Morepen Laboratories today announced that its PAT surged by 394 per cent Y-o-Y to ₹56.35 crore in the June quarter, supported by better operating leverage and improved performance on API front.
Drug firm Morepen Laboratories on Tuesday reported an over two-fold rise in its consolidated net profit at Rs 26.76 crore for the quarter ended March 31, 2021, on account of higher revenue
The Q3 FY 2017-18 financial results were taken on record at a meeting of the company's board of directors here on Monday